title: Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience.
abstract: BACKGROUND
  Recurrence of hepatitis C virus (HCV) in hepatic allograft is a major concern after successful liver transplant (LTx).
  
  
  OBJECTIVE
  To examine the response rate to pegylated interferon (PEG-IFN) and ribavirin in post-LTx patients with HCV recurrence.
  
  
  METHODS
  Between January 2003 and September 2006, 60 patients with biopsy proven HCV recurrence (46 males and 14 females) received PEG-IFN 2a (n = 40) or IFN 2b (n = 20) with ribavirin. All patients were followed until July 2007.
  
  
  RESULTS
  Fourteen patients (23.3%) tolerated antiviral therapy for less than six months and 10 (16.7%) discontinued therapy between six and 11 months. PEG-IFN dose was reduced in 21 (35%) patients and ribavirin dose was reduced in 16 (26.7%) patients. Overall, 55% patients achieved end of treatment response (EOT) and 35% sustained virological response (SVR). Mean Hepatitis Activity Index and Fibrosis Score pre-therapy was 5.8 +/- 1.9 and 1.7 +/- 1.3 and post-therapy, it was 4.4 +/- 2.1 and 2.4 +/- 1.6, respectively. Overall, three yr patient and graft survival was 73.9% and 69.2%, respectively. The patients with SVR had significantly lower viral load compared with other groups (p = 0.028).
  
  
  CONCLUSIONS
  PEG-IFN and ribavirin therapy achieved 55% EOT and 35% SVR; 60% patients tolerated therapy. Biochemical response was observed in all groups of patients irrespective of virological response.
authors.affiliation: Department of Surgery, Division of Solid Organ Transplantation, University of Rochester Medical Center, Rochester, NY, USA. ashok_jain@urmc.rochester.edu
authors.forename: Ashok
authors.initials: A
authors.lastname: Jain
authors.forename: Rajeev
authors.initials: R
authors.lastname: Sharma
authors.forename: Charlotte
authors.initials: C
authors.lastname: Ryan
authors.forename: Saman
authors.initials: S
authors.lastname: Safadjou
authors.forename: Randeep
authors.initials: R
authors.lastname: Kashyap
authors.forename: Parvez
authors.initials: P
authors.lastname: Mantry
authors.forename: Benedict
authors.initials: B
authors.lastname: Maliakkal
authors.forename: Mark
authors.initials: M
authors.lastname: Orloff
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012008:Recurrence; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a